Skip to main content

OSI Pharmaceuticals Signs Agreement to Evaluate Horizon Discovery Cell Lines

NEW YORK (GenomeWeb News) – The Cambridge, UK-based translational genomics company Horizon Discovery announced today that it has signed a non-exclusive commercial agreement with OSI Pharmaceuticals. Under the agreement, OSI will evaluate nine of Horizon’s X-MAN cell lines and matched cells with normal genetic backgrounds for 12 months, starting this month.
 
OSI intends to characterize the cell lines and to use them for testing both known and internally developed compounds directed at genotypes of interest. The company will share key datasets with Horizon during that evaluation period. In addition, Horizon and OSI will reportedly work together to generate new data for research areas in which both companies are interested.
 
The X-MAN lines are isogenic human cell lines representing genetically defined in vitro models of human cancer. The cancerous and non-cancerous cell types were developed to aid in drug discovery and help assess treatments in clinical trials.
 
Financial terms of the agreement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.